Cargando…

Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐X(L)–BAX interaction

Tumor cells undergo senescence in response to both conventional and targeted cancer therapies. The induction of senescence in response to cancer therapy can contribute to unfavorable patient outcomes, potentially including disease relapse. This possibiliy is supported by our findings that tumor cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saleh, Tareq, Carpenter, Valerie J., Tyutyunyk‐Massey, Liliya, Murray, Graeme, Leverson, Joel D., Souers, Andrew J., Alotaibi, Moureq R., Faber, Anthony C., Reed, Jason, Harada, Hisashi, Gewirtz, David A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530780/ https://www.ncbi.nlm.nih.gov/pubmed/32652830 http://dx.doi.org/10.1002/1878-0261.12761

Ejemplares similares

Studies of Non-Protective Autophagy Provide Evidence that Recovery from Therapy-Induced Senescence is Independent of Early Autophagy
por: Saleh, Tareq, et al.
Publicado: (2020)

The Senolytic Drug Navitoclax (ABT-263) Causes Trabecular Bone Loss and Impaired Osteoprogenitor Function in Aged Mice
por: Sharma, Anuj K., et al.
Publicado: (2020)

EA.hy926 Cells and HUVECs Share Similar Senescence Phenotypes but Respond Differently to the Senolytic Drug ABT-263
por: Abdelgawad, Ibrahim Y., et al.
Publicado: (2022)

Treatment of advanced atherosclerotic mice with the senolytic agent ABT-263 is associated with reduced indices of plaque stability and increased mortality
por: Karnewar, Santosh, et al.
Publicado: (2023)

Effects and Related Mechanisms of the Senolytic Agent ABT-263 on the Survival of Irradiated A549 and Ca9-22 Cancer Cells
por: Sato, Kota, et al.
Publicado: (2021)

Taking Advantage of the Senescence-Promoting Effect of Olaparib after X-ray and Proton Irradiation Using the Senolytic Drug, ABT-263
por: Huart, Camille, et al.
Publicado: (2022)

Senolytics for Cancer Therapy: Is All that Glitters Really Gold?
por: Carpenter, Valerie J., et al.
Publicado: (2021)

Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
por: Ritter, Violetta, et al.
Publicado: (2021)

Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax
por: Ackler, Scott, et al.
Publicado: (2015)

The Combination of Radiation with PARP Inhibition Enhances Senescence and Sensitivity to the Senolytic, Navitoclax, in Triple Negative Breast Tumor Cells
por: Softah, Abrar, et al.
Publicado: (2023)

Correction to: Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
por: Ritter, Violetta, et al.
Publicado: (2022)

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
por: Phillips, D C, et al.
Publicado: (2015)

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
por: Phillips, D C, et al.
Publicado: (2016)

Inhibition of antiapoptotic BCL-2 proteins with ABT-263 induces fibroblast apoptosis, reversing persistent pulmonary fibrosis
por: Cooley, Joseph C., et al.
Publicado: (2023)

Combination of fenretinide and ABT-263 induces apoptosis through NOXA for head and neck squamous cell carcinoma treatment
por: Britt, Erin L., et al.
Publicado: (2019)

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
por: Touzeau, C, et al.
Publicado: (2014)

ABT-263 Reduces Hypertrophic Scars by Targeting Apoptosis of Myofibroblasts
por: Yang, Xiaolan, et al.
Publicado: (2021)

NOXA expression is downregulated in human breast cancer undergoing incomplete pathological response and senescence after neoadjuvant chemotherapy
por: Al Shboul, Sofian, et al.
Publicado: (2023)

JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancer
por: Wang, Huogang, et al.
Publicado: (2017)

Clearance of senescent cells with ABT-263 improves biological functions of synovial mesenchymal stem cells from osteoarthritis patients
por: Miura, Yugo, et al.
Publicado: (2022)

The Bcl-2/Bcl-xL Inhibitor ABT-263 Attenuates Retinal Degeneration by Selectively Inducing Apoptosis in Senescent Retinal Pigment Epithelial Cells
por: Ryu, Wonseon, et al.
Publicado: (2023)

CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263
por: Huang, Tianlu, et al.
Publicado: (2019)

Antihelminthic benzimidazoles potentiate navitoclax (ABT-263) activity by inducing Noxa-dependent apoptosis in non-small cell lung cancer (NSCLC) cell lines
por: Lam, Lloyd T, et al.
Publicado: (2015)

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
por: Leverson, J D, et al.
Publicado: (2015)

The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells
por: Wang, Bin, et al.
Publicado: (2014)

BAX and BAK1 are dispensable for ABT-737-induced dissociation of the BCL2-BECN1 complex and autophagy
por: Pedro, Jose Manuel Bravo-San, et al.
Publicado: (2015)

Efficient Elimination of Cancer Cells by Deoxyglucose-ABT-263/737 Combination Therapy
por: Yamaguchi, Ryuji, et al.
Publicado: (2011)

Synergistic Effects of TW-37 and ABT-263 on Renal Cell Carcinoma Cells
por: Yu, Rui, et al.
Publicado: (2021)

ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer
por: Chen, Qiongrong, et al.
Publicado: (2015)

KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib
por: Wang, Guihua, et al.
Publicado: (2019)

Mcl-1 levels need not be lowered for cells to be sensitized for ABT-263/737-induced apoptosis
por: Yamaguchi, R, et al.
Publicado: (2011)

Single Agent and Synergistic Activity of Maritoclax with ABT-263 in Nasopharyngeal Carcinoma (NPC) Cell Lines
por: Xiang, Benedict Lian Shi, et al.
Publicado: (2020)

Human Pluripotent Stem Cells and Derived Neuroprogenitors Display Differential Degrees of Susceptibility to BH3 Mimetics ABT-263, WEHI-539 and ABT-199
por: García, Carolina Paola, et al.
Publicado: (2016)

ABT-263 Enhances Sensitivity to Metformin and 2-Deoxyglucose in Pediatric Glioma by Promoting Apoptotic Cell Death
por: Levesley, Jane, et al.
Publicado: (2013)

Data on the DNA damaging and mutagenic potential of the BH3-mimetics ABT-263/Navitoclax and TW-37
por: Green, Maja M., et al.
Publicado: (2016)

Combining Paclitaxel with ABT-263 Has a Synergistic Effect on Paclitaxel Resistant Prostate Cancer Cells
por: Wang, Chihuei, et al.
Publicado: (2015)

Navitoclax (ABT263) reduces inflammation and promotes chondrogenic phenotype by clearing senescent osteoarthritic chondrocytes in osteoarthritis
por: Yang, Hao, et al.
Publicado: (2020)

ABT-263 enhanced bacterial phagocytosis of macrophages in aged mouse through Beclin-1-dependent autophagy
por: Zhang, Yu, et al.
Publicado: (2021)

The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA
por: Muenchow, Alina, et al.
Publicado: (2020)

BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation
por: Zhan, Yihong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bs8kc68qgngclrr17t8o70pvf0